Better Health, Brighter Future
Additionally, PLM and Takeda are participating in a partnership with other companies to develop a global standard measure of patient experience, burden, and activation in Phase II/III clinical trials. The framework is a necessary tool to better measure and understand the actual experience and feedback of patients who participate in clinical trials.
1.Burisch J and Munkholm P. The epidemiology of inflammatory bowel disease. Scandinavian Journal of Gastroenterology. 2015; 50: 942–951.